<DOC>
	<DOCNO>NCT01241539</DOCNO>
	<brief_summary>The current study allow assessment pharmacokinetics , pharmacodynamics , elimination rate clearance dabigatran etexilate follow haemodialysis ESRD patient .</brief_summary>
	<brief_title>Pharmacokinetics Dabigatran Etexilate ( PradaxaÂ® ) During Haemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : End stage renally disease ( ESRD ) , undergo haemodialysis ESRD patient relatively good health Age 21 60 year inclusive Signed dated write informed consent prior admission study Exclusion criterion : Clinically relevant laboratory physical examination abnormality ( except renal function test deviation clinical laboratory value ) relate renal impairment Moderate severe concurrent liver function impairment Surgery gastrointestinal tract ( except appendectomy herniotomy ) evidence significant gastrointestinal motility problem Recent contemplate diagnostic therapeutic procedure potential uncontrollable bleed Intake medication , influence blood clot Subjects able understand comply protocol requirement , instruction protocolstated restriction For woman childbearing potential : reliable contraception Participation another trial investigational drug ( &lt; 2 month prior administration trial ) Scheduled receive donor kidney transplant course study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>